Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — UBS Global Life Sciences Conference 2006

25 slides from Pharmacopeia's conference presentation, Sep 28, 2006

  1. Slide 1: UBS Global Life Sciences Conference

    Slide 1: UBS Global Life Sciences Conference

    Leslie J. Browne President & CEO UBS Global Life Sciences Conference September 28th, 2006 Discovering excellence, driving clinical success TM

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which exp

  3. Slide 3: Value Drivers - Balanced Risk

    Slide 3: Value Drivers - Balanced Risk

    Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Strong, sustainable pipeline Leader in developing DARA Dual acting angiotensin and endothelin receptor antagonists for kidney diseases First-in-class DARA on track to file IND in 1Q-07 Deep p

  4. Slide 4: Business Strategy – More Ownership

    Slide 4: Business Strategy – More Ownership

    Selected Indications Partner Retain candidates at least to clinical validation with the option to continue alone to NDA for selected indications or partner for Ph III clinical development Former business Lead Discovery Lead Optimization Preclinical Development Phase 1 Phase 2 Phase 3 Partner Busines

  5. Slide 5: Balancing Risk to Build Value

    Slide 5: Balancing Risk to Build Value

    Balancing Risk to Build Value 8 Million Compound Library Largest in the Industry Integrated HTS Medicinal Chemistry Pharmacology Development GSK Cephalon Organon Schering-Plough Bristol-Myers Squibb Unique Discovery Platform Strategic Partnerships Intellectual Property High Value Portfolio Pharmacop

  6. Slide 6: Pharmacopeia Strengths

    Slide 6: Pharmacopeia Strengths

    Pharmacopeia Strengths Strong sustainable pipeline Partnered development programs Strong strategic partnerships Financials

  7. Slide 7: Internal Programs

    Slide 7: Internal Programs

    Internal Programs Robust Growing Internal Pipeline DARA in preclinical development approaching IND Optimization focused on JAK3, CCR1 and A 2A Preclinical Program Worldwide Rights Lead Generation Optimization Development IND Filing PS433540 Cardiovascular DARA Pharmacopeia PS608504 Transplantation J

  8. Slide 8: DARA – First-in-class

    Slide 8: DARA – First-in-class

    DARA – First-in-class ET-1 ET-1 ET-1 A II A II A II Combines the properties of two marketed cardiovascular product classes in a single molecule Selectively blocks Angiotensin (AT1) and Endothelin (ETA) Strong preclinical and clinical data Potential in resistant hypertensions and chronic renal diseas

  9. Slide 9: Preclinical Results - Hypertension and Heart Failure

    Slide 9: Preclinical Results - Hypertension and Heart Failure

    ET-1 ET-1 ET-1 A II A II A II Angiotensin II and Endothelin – potent mitogens Vasoconstriction Tissue proliferation/fibrosis Inflammation Preclinical Results - Hypertension and Heart Failure PS433540 (BMS-456567) potent antihypertensive in predictive rat hypertension models (SHR and DOCA) ET 1 and A

  10. Slide 10: PS433540 – Antihypertensive Activity

    Slide 10: PS433540 – Antihypertensive Activity

    PS433540 reduces blood pressure more than irbesartan at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Telemeterized Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity PS433540

  11. Slide 11: Clinical Results – Diabetic nephropathy

    Slide 11: Clinical Results – Diabetic nephropathy

    ET-1 ET-1 ET-1 A II A II A II Angiotensin II and Endothelin – potent mitogens Vasoconstriction Tissue proliferation/fibrosis Inflammation Clinical Results – Diabetic nephropathy Improved renal hemodynamics Marked decrease in urinary albumin excretion rate and proteinuria in Phase II studies ET 1 and

  12. Slide 12: Chronic Kidney Disease – Medical need

    Slide 12: Chronic Kidney Disease – Medical need

    Chronic Kidney Disease – Medical need Progressive disease leading to dialysis and transplant Underlying disease causes Diabetes Hypertension Obesity Glomerulonephritis Cystic kidney – most common causes of end-stage renal disease 20 million in US suffer from chronic kidney disease 5% of US populatio

  13. Slide 13: Chronic Kidney Disease – Current Rx

    Slide 13: Chronic Kidney Disease – Current Rx

    Chronic Kidney Disease – Current Rx Angiotensin Receptor Blockers Approved Avapro® (irbesartan) and Cozaar® (losartan) ACE Inhihitors recommended Usage in patients Elevated serum creatinine Proteinuria (>300 mg/day) in patients with hypertension Reduces the progression of nephropathy Compounds Under

  14. Slide 14: Current Status

    Slide 14: Current Status

    Current Status ARBs approved for diabetic nephropathy Benefit demonstrated for investigational ET blocker in combination with ARB in Phase II trials Opportunity for DARA To file IND by 1Q-07 To evaluate antihypertensive activity in Phase Ib To demonstrate dual activity in humans (ET and ARB) in Ph I

  15. Slide 15: DARA Development Summary

    Slide 15: DARA Development Summary

    DARA Development Summary Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 3Q-06 File IND 1Q-07 ‘First in man’ dosing 1Q-07 Initiate Phase Ib hypertension study End-07 Initiate Ph II 2H-08

  16. Slide 16: Pharmacopeia Strengths

    Slide 16: Pharmacopeia Strengths

    Pharmacopeia Strengths Strong sustainable pipeline Partnered development programs Strong strategic partnerships Financials

  17. Slide 17: Proven Track Record of Success

    Slide 17: Proven Track Record of Success

    Proven Track Record of Success Significant milestone (~$100MM total) and royalty interests without further Pharmacopeia investment Preclinical Clinical Phase Program Worldwide Rights Lead Generation Optimization Development I II III NDA Filed PS540446 Rheumatoid Arthritis p38 Bristol Myers Squibb PS

  18. Slide 18: Clinical Pipeline Advancing

    Slide 18: Clinical Pipeline Advancing

    Clinical Pipeline Advancing Partnered clinical programs approaching Phase II p38 kinase inhibitors for RA with Bristol-Myers Squibb Well tolerated in multiple Phase I trials Currently in Ra patients receiving methotrexate Back up compound entered Phase I study December, 2005 CXCR2 antagonist for COP

  19. Slide 19: Pharmacopeia Strengths

    Slide 19: Pharmacopeia Strengths

    Pharmacopeia Strengths Strong sustainable pipeline Partnered development programs Strong strategic partnerships Financials

  20. Slide 20: Strategic Partnerships

    Slide 20: Strategic Partnerships

    Strategic Partnerships Late stage optimization programs Upfront $15 million technology access fee Up to $35 million per program in milestones Double-digit royalties Builds portfolio and financial runway Pharmacopeia prosecutes Phase I and Phase II Non-dilutive tranched financing - $15 million Up to

  21. Slide 21: Pharmacopeia Strengths

    Slide 21: Pharmacopeia Strengths

    Pharmacopeia Strengths Strong sustainable pipeline Partnered development programs Strong strategic partnerships Financials

  22. Slide 22: Financial Summary

    Slide 22: Financial Summary

    Financial Summary For the 6 Months Ended June 30, 2006 $7.4 million in net revenue $14.9 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $30.4 million as of December 31 st , 2005 $40.1 million as of June 30, 2006 Received $20 million of f

  23. Slide 23: Milestones from January 2006

    Slide 23: Milestones from January 2006

    Milestones from January 2006 Within 12-months Two internal candidates in pre-clinical development One or more partnered programs in clinical Phase II Strategic partnership with significant retained rights Core clinical-regulatory capability added Year end cash and short term investments of $30-35MM

  24. Slide 24: Pharmacopeia Transformed

    Slide 24: Pharmacopeia Transformed

    Pharmacopeia Transformed DARA approaching IND First-in-class treatment in large markets – IND 1Q-07 Partnered clinical programs approaching Phase II p38 kinase inhibitor for RA with Bristol-Myers Squibb CXCR2 antagonist for COPD with Schering-Plough Portfolio of programs for immunological diseases J

  25. Slide 25: Discovering excellence, driving clinical success

    Slide 25: Discovering excellence, driving clinical success

    Discovering excellence, driving clinical success TM

Source: SEC EDGAR · 8-K filed Sep 28, 2006

More decks from Pharmacopeia Inc